ClinicalTrials.gg
CompletedNCT00325143Updated Jun 6, 2018Results posted

Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine

A Phase 3 interventional study of DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccine in Haemophilus Influenzae Type b, Diphtheria and Tetanus, sponsored by GlaxoSmithKline. Completed at 3 sites in Singapore. Open to participants aged 11 Weeks to 17 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
702
Allocation
Non-randomized
Ages
11 Weeks to 17 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Haemophilus Infections — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Haemophilus Infections.

Enrollment
2nd of 13
702 · median 494
Started
2003
with 1 other
Phase 3
7 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
12 of 13
GlaxoSmithKline

Among the 13 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Haemophilus Infections, this one is the 2nd largest by enrollment, is one of 2 that started in 2003, is one of 7 in phase 3, and was the 1st registered.

Haemophilus Infections

176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.

Browse Haemophilus Infections studies →

Open to participants now

None of the 13 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Haemophilus Infections is open now. The open studies under Haemophilus Infections, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 11 Weeks to 17 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Haemophilus Infections as a file.
02

Study summary

To assess the safety and reactogenicity of the DTPa-HBV-IPV/Hib vaccine and DTPa-IPV/Hib vaccine. This DTPa-IPV/Hib vaccine given at 3 and 4 months of age is co-administered with GSK Biologicals' rotavirus vaccine or Placebo. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Read the detailed description

Single group study. Subjects in GSK Biologicals' rotavirus study (Rota-028) in Singapore will be enrolled in this study.

03

Conditions studied

  • Haemophilus Influenzae Type b
  • Diphtheria
  • Tetanus
  • Poliomyelitis
  • Acellular Pertussis
04

Who can participate

Ages eligible
11 Weeks to 17 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have been enrolled in the Rota-028 study.
  • Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female between, and including, 11 and 17 weeks of age at the time of the first vaccination.
  • Written obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Subjects should have received two doses of vaccine: at birth and at approximately one month of age.

Exclusion criteria

Exclusion criteria

  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs during the study period.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of the vaccine and ending 30 days after.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including (HIV) infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Major congenital defects or serious chronic illness.
  • History of any neurologic disorders or seizures.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
702 participants (actual)

Study arms

  • Experimental
    Infanrix Hexa Group

    Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.

    Biological: DTPa-HBV-IPV/Hib · Biological: DTPa-IPV/Hib vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects Reporting Any Solicited Local Symptoms

    Assessed solicited local and general symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses

  2. Number of Subjects Reporting Any Solicited General Symptoms

    Assessed solicited general symptoms were drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses

Secondary outcomes

  1. Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: During the 31-day (Days 0-30) post-vaccination period

  2. Number of Subjects Reporting Any Large Swelling Reactions

    A large swelling reaction was defined as swelling with a diameter greater than (\>) 50 millimeters (mm), noticeable diffuse swelling or noticeable increase of limb circumference.

    Time frame: At Month 15, post-booster dose

  3. Number of Subjects Reporting Any Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: During the entire study period (from Month 0 up to Month 21)

07

Results

Posted Feb 7, 2017

Participant flow

Participant flow — Overall Study
MilestoneInfanrix Hexa Group
Started702
Completed676
Not completed26
Withdrew: Lost to follow-up(complete vacc. course)13
Withdrew: Migrated/moved from study area1
Withdrew: Lost to follow-up(incompl. vacc. course)4
Withdrew: Withdrawal by subject8

Outcome measures

PrimaryNumber of Subjects Reporting Any Solicited Local Symptoms

Assessed solicited local and general symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Solicited Local Symptoms
ParticipantsInfanrix Hexa Group
Any Pain, Dose 1130
Any Redness, Dose 1120
Any Swelling, Dose 189
Any Pain, Dose 2134
Any Redness, Dose 2137
Any Swelling, Dose 2100
Any Pain, Dose 397
Any Redness, Dose 3126
Any Swelling, Dose 3100
Any Pain, Booster dose166
Any Redness, Booster dose148
Any Swelling, Booster dose115
Any Pain, Across doses301
Any Redness, Across doses273
Any Swelling, Across doses215
PrimaryNumber of Subjects Reporting Any Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Solicited General Symptoms
ParticipantsInfanrix Hexa Group
Any Drowsiness, Dose 1165
Any Temperature (Axillary) (°C), Dose 1139
Any Irritability, Dose 1229
Any Loss of appetite, Dose 1173
Any Drowsiness, Dose 2140
Any Temperature (Axillary) (°C), Dose 2124
Any Irritability, Dose 2192
Any Loss of appetite, Dose 2155
Any Drowsiness, Dose 3106
Any Temperature (Axillary) (°C), Dose 3100
Any Irritability, Dose 3161
Any Loss of appetite, Dose 3106
Any Drowsiness, Booster dose89
Any Temperature (Axillary) (°C), Booster dose152
Any Irritability, Booster dose163
Any Loss of appetite, Booster dose118
Any Drowsiness, Across doses290
Any Temperature (Axillary) (°C), Across doses330
Any Irritability, Across doses381
Any Loss of appetite, Across doses324
SecondaryNumber of Subjects Reporting Any Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
During the 31-day (Days 0-30) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)
ParticipantsInfanrix Hexa Group
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)321
SecondaryNumber of Subjects Reporting Any Large Swelling Reactions

A large swelling reaction was defined as swelling with a diameter greater than (\>) 50 millimeters (mm), noticeable diffuse swelling or noticeable increase of limb circumference.

Time frame:
At Month 15, post-booster dose
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Large Swelling Reactions
ParticipantsInfanrix Hexa Group
Number of Subjects Reporting Any Large Swelling Reactions0
SecondaryNumber of Subjects Reporting Any Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
During the entire study period (from Month 0 up to Month 21)
Reported as:
Count of participants · Participants
Number of Subjects Reporting Any Serious Adverse Events (SAEs)
ParticipantsInfanrix Hexa Group
Number of Subjects Reporting Any Serious Adverse Events (SAEs)108

Adverse events

Collected over Solicited local/general symptoms: during the 4-day (Days 0-3) post-vaccination period; Unsolicited AE(s): during the 30-day (Days 0-29) post-vaccination period; SAE(s): during the entire study period (Month 0 to Month 21).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infanrix Hexa Group0/702 (0%)108/702 (15.4%)594/702 (84.6%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventInfanrix Hexa Group
BronchiolitisInfections and infestations30/702
Febrile convulsionNervous system disorders13/702
GastroenteritisInfections and infestations11/702
Upper respiratory tract infectionInfections and infestations11/702
Gastritis viralInfections and infestations7/702
Head injuryInjury, poisoning and procedural complications5/702
AsthmaRespiratory, thoracic and mediastinal disorders5/702
Urinary tract infectionInfections and infestations5/702
Escherichia urinary tract infectionInfections and infestations4/702
Gastroenteritis viralInfections and infestations4/702
Most frequent other events
Showing 10 of 11
Most frequent other events
EventInfanrix Hexa Group
IrritabilityGeneral disorders381/697
Fever (Axillary) (°C)General disorders330/697
Loss of appetiteGeneral disorders324/697
PainGeneral disorders301/697
DrowsinessGeneral disorders290/697
RednessGeneral disorders273/697
SwellingGeneral disorders215/697
Upper respiratory tract infectionInfections and infestations125/702
PyrexiaGeneral disorders46/702
DiarrhoeaGastrointestinal disorders40/702

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)Infanrix Hexa Group
Mean13.5 ± 0.99
Sex: Female, Male
Sex: Female, Male(Participants)Infanrix Hexa Group
Female349
Male353
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Infanrix Hexa Group
White/Caucasian1
Japanese1
Not specified27
Chinese366
Malay269
Indian38
08

Study locations

3 sites
  • GSK Investigational Site
    Singapore, 119074, Singapore
  • GSK Investigational Site
    Singapore, 228510, Singapore
  • GSK Investigational Site
    Singapore, 229899, Singapore
09

References and documents

Publications

  • Lim FS, Phua KB, Lee BW, Quak SH, Teoh YL, Ramakrishnan G, Han HH, Van Der Meeren O, Jacquets JM, Bock HL. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting. Southeast Asian J Trop Med Public Health. 2011 Jan;42(1):138-47. PubMed 21323176 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 10 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2006
First posted
May 12, 2006
Start
Dec 1, 2003
Primary completionActual
Feb 1, 2007
CompletionActual
Feb 1, 2007
Results first posted
Feb 7, 2017
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00325143
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 12, 2006
Start date
Dec 1, 2003
Primary completion
Feb 1, 2007
Completion
Feb 1, 2007
Results posted
Feb 7, 2017
Last update
Jun 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion